ArticleRespiratory research2026
PPP2R2C promotes aerobic glycolysis and mediates pemetrexed resistance in lung adenocarcinomas by upregulating TCP1-dependent protein folding of glycolytic enzymes.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) remains lethal primarily due to its tendency for early metastasis and the universal development of chemotherapy resistance. The results of this study delineate a coherent signaling axis, originating from the upregulation of PPP2R2C expression to metabolic reprogramming, which ultimately influences the malignant progression and chemotherapy resistance of LUAD.
methodsGEPIA analysis was used to evaluate PPP2R2C expression in NSCLC. Following shRNA-mediated knockdown, cell proliferation, migration, apoptosis, and glycolytic activity were assessed in NCI-H1299 and A549 cells. Subcutaneous tumor formation was evaluated four weeks after injection of LV-shPPP2R2C or control vector, followed by H&E staining and immunohistochemical analysis of PPP2R2C and Ki67.
resultsClinical analysis shows that PPP2R2C is highly expressed in LUAD and is associated with poor prognosis, lymph node metastasis, and advanced disease stage. In vitro knockdown of PPP2R2C suppresses proliferation and migration and promotes apoptosis. Mechanistically, PPP2R2C drives the Warburg effect by upregulating the molecular chaperone TCP1 to ensure proper folding of glycolytic enzymes. Blocking TCP1 or glycolysis (with 2-DG) reverses PPP2R2C-mediated survival advantage and pemetrexed resistance. In vivo experiments confirm that knocking down PPP2R2C or TCP1 similarly inhibits tumor growth and restores chemotherapy sensitivity.
conclusionsIn summary, the results elucidate a novel mechanism whereby PPP2R2C enhances glycolysis by regulating TCP1-dependent protein refolding, thereby driving LUAD progression and chemoresistance. Thus, this study establishes a strong rationale for targeting this pathway as a potential therapeutic approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.